sábado, 14 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

The Walt Disney Company Reports First Quarter Earnings for Fiscal 2026

View original at finance.yahoo.com
“On track to repurchase $7 billion of stock”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Experiences segment operating income will show high-single digit growth for full year FY2026, weighted to second half

    80% confidence
  • Cash from operations will be $19B for full year FY2026

    80% confidence
  • Entertainment segment operating income will be comparable to Q2 FY2025 in Q2 FY2026

    80% confidence
  • Entertainment segment operating income will show double-digit growth for full year FY2026, weighted to second half

    80% confidence
  • SVOD operating margin will reach 10% for full year FY2026

    80% confidence
  • Sports segment operating income will decline by $100M in Q2 FY2026

    80% confidence
  • Disney delivered strong box office performance in calendar year 2025 with billion-dollar hits like Zootopia 2 and Avatar: Fire and Ash, franchises that generate value across many of Disney's businesses

    80% confidence
  • Adjusted EPS will show double-digit growth for full year FY2026

    80% confidence
  • CEO is incredibly proud of all that Disney has accomplished over the past three years

    80% confidence
  • Disney is pleased with the start to fiscal year 2026 and achievements reflect tremendous progress made

    80% confidence
  • SVOD operating income will be approximately $500M in Q2 FY2026, representing $200M increase over Q2 FY2025

    80% confidence
  • Disney is on track with $7B stock repurchase program for FY2026

    80% confidence
  • Sports segment operating income will show low-single digit growth for full year FY2026

    80% confidence

Data points we hold from this source

The Walt Disney Company · corporate expenses304000000 USD
The Walt Disney Company · current borrowings10800000000 USD
The Walt Disney Company · depreciation1000000000 USD
The Walt Disney Company · diluted eps1.40 USD
The Walt Disney Company · domestic parks capex2300000000 USD
The Walt Disney Company · entertainment capex293000000 USD
The Walt Disney Company · long term debt35800000000 USD
The Walt Disney Company · treasury stock9500000000 USD
The Walt Disney Company · interest expense net275000000 USD
The Walt Disney Company · income before taxes3700000000 USD
The Walt Disney Company · international parks capex357000000 USD
The Walt Disney Company · total equity114000000000 USD
The Walt Disney Company · receivables15100000000 USD
The Walt Disney Company · capital expenditures3000000000 USD
The Walt Disney Company · total assets202100000000 USD
The Walt Disney Company · cash from operations735000000 USD
The Walt Disney Company · tax rate32.7 percent
The Walt Disney Company · segment operating income5100000000 USD
The Walt Disney Company · adjusted eps1.76 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,580 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Walt Disney Company Reports First Quarter Earnings for Fiscal 2026 — Source | Via News | es.via.news